Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes
Patients with T2D starting tirzepatide had greater HbA1c and weight reductions at 12 months post-initiation than those on injectable semaglutide, regardless of previous GLP-1 RA use, consistent with previous clinical trial results.
Authors
- Meredith M. Hoog (ORCID: https://orcid.org/0009-0000-1954-847X)
- Carlos R. Vallarino (ORCID: https://orcid.org/0000-0002-0929-2260)
- Juan M. Maldonado (ORCID: https://orcid.org/0000-0002-1370-327X)
- Kendra A. Terrell (ORCID: https://orcid.org/0009-0008-0915-3982)
- Michael Grabner (ORCID: https://orcid.org/0000-0002-6521-1007)
- Emma Richard
- Chia‐Chen Teng
Institutions
- Eli Lilly (United States) (US)
- Wilmington University (US)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1007/s13300-025-01794-9
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59